Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) and raises the price target from $34 to $37.
August 06, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences and raises the price target from $34 to $37.
The raised price target and maintained Outperform rating by a reputable analyst is likely to positively impact investor sentiment and drive short-term price appreciation for CSTL.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100